Ticker
ABCL

Price
4.34
Stock movement down
-0.26 (-5.65%)
Company name
Abcellera Biologics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
1.25B
Ent value
1.17B
Price/Sales
2.57
Price/Book
1.01
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
7.88
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-69.35%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2023-11-21
AbCellera Biologics Inc. (NASDAQ:NASDAQ:ABCL) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal...
November 3, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
November 2, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ABCL does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E7.88
Price to OCF4.50
Price to FCF6.10
Price to EBITDA4.59
EV to EBITDA4.30

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.57
Price to Book1.01
EV to Sales2.41
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
November 1, 2023

iO Charts is a Seeking Alpha partner

AbCellera's Q2 2023 financials reveal declining revenues and high R&D expenses, leading to caution in investment decision. Learn why I rate ABCL stock a hold.
September 25, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count287.69M
EPS (TTM)0.50
FCF per share (TTM)0.65

Income statement

Loading...
Income statement data
Revenue (TTM)485.43M
Gross profit (TTM)418.99M
Operating income (TTM)218.19M
Net income (TTM)158.52M
EPS (TTM)0.50
EPS (1y forward)-0.65

Margins

Loading...
Margins data
Gross margin (TTM)86.31%
Operating margin (TTM)44.95%
Profit margin (TTM)32.66%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash386.54M
Net receivables103.41M
Total current assets1.03B
Goodwill47.81M
Intangible assets131.50M
Property, plant and equipment0.00
Total assets1.54B
Accounts payable14.83M
Short/Current long term debt82.26M
Total current liabilities118.32M
Total liabilities307.63M
Shareholder's equity1.23B
Net tangible assets1.05B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)277.36M
Capital expenditures (TTM)72.66M
Free cash flow (TTM)204.70M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity12.85%
Return on Assets10.29%
Return on Invested Capital12.80%
Cash Return on Invested Capital16.52%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open4.58
Daily high4.58
Daily low4.32
Daily Volume1.44M
All-time high53.20
1y analyst estimate28.33
Beta-0.09
EPS (TTM)0.50
Dividend per share-
Ex-div date-
Next earnings date19 Feb 2024

Downside potential

Loading...
Downside potential data
ABCLS&P500
Current price drop from All-time high-91.84%-5.12%
Highest price drop-92.65%-56.47%
Date of highest drop27 Oct 20239 Mar 2009
Avg drop from high-72.05%-11.48%
Avg time to new high148 days13 days
Max time to new high708 days1805 days
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
September 20, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
September 13, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABCL (Abcellera Biologics Inc) company logo
Marketcap
1.25B
Marketcap category
Small-cap
Description
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
495
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
AbCellera Biologics Inc. (NASDAQ:NASDAQ:ABCL) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal &...
August 4, 2023

iO Charts is a Seeking Alpha partner

The following slide deck was published by AbCellera Biologics Inc.
August 3, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
August 3, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
August 2, 2023
AbCellera Biologics presents a complex yet intriguing investment case. Click here to see why ABCL stock is a Hold.
July 19, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
July 13, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
May 24, 2023
AbCellera reported Q1 2023 results on May 4th. While it appears to have no clear catalyst to rise in the short term, see why I rate ABCL stock a Buy.
May 6, 2023
AbCellera Biologics Inc. (NASDAQ:NASDAQ:ABCL) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and...
May 5, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
May 4, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
May 3, 2023
AbCellera is pledging to discover promising antibodies for its clients and bring them to the clinic faster than anybody else. Read more about ABCL and the challenges it faces.
March 24, 2023
iO Charts is a Seeking Alpha partnerNext page